Nasal spray may reduce breathing risks during ERCP sedation

This study tested whether adding a dexmedetomidine nasal spray to standard propofol sedation could reduce breathing problems and improve recovery for people undergoing ERCP, a procedure to examine bile and pancreatic ducts. 180 adults aged 18-70 were randomly assigned to receive the nasal spray, an intravenous version of the same drug, or propofol alone. The main goal was to see if the nasal spray lowered the chance of low blood oxygen during the procedure.